Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Interferon alfa treatment of early primary myelofibrosis is associated with improved overall survival

View Full Paper
Ask AI
Bookmark
Share

Authors

MRMlaak RobMAMajed Al-NazerJSJoseph M. Scandura

Discussion

Loading...

Member takes

Overview

Comparative cohort study reveals treatment with interferon alfa enhances overall survival in primary myelofibrosis, suggesting effective intervention strategies.

Key Points

  • Overall survival improved with interferon alfa treatment in early primary myelofibrosis patients.
  • The median overall survival was significantly longer at 18 years with interferon, compared to 14 years without.
  • Cox proportional-hazards models demonstrated the survival benefit of interferon was independent of age and risk factors.
  • Future randomized controlled trials are essential to validate the benefits of interferon in early primary myelofibrosis treatment.

Cite This Study

Rob et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d79chttps://doi.org/10.1182/blood-2025-2043
View Full Paper
Ask AI
Bookmark
Share